BPTH (Bio-Path Holdings) Shiller PE Ratio: (As of Sep. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bio-Path Holdings Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bio-Path Holdings  (OTCPK:BPTH) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Bio-Path Holdings Shiller PE Ratio Related Terms


Bio-Path Holdings Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Bio-Path Holdings's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Path Holdings Shiller PE Ratio Chart

Bio-Path Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bio-Path Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BPTH vs CDT, CLSDQ, ABPO: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Bio-Path Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Path Holdings Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's Shiller PE Ratio falls into.



Bio-Path Holdings Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Bio-Path Holdings's E10 for the quarter that ended in Mar. 2026 is calculated as:

For example, Bio-Path Holdings's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.03/330.2130*330.2130
=-0.030

Current CPI (Mar. 2026) = 330.2130.

Bio-Path Holdings Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201603 -80.000 238.132 -110.934
201606 -80.000 241.018 -109.606
201609 -80.000 241.428 -109.420
201612 -52.000 241.432 -71.122
201703 -16.000 243.801 -21.671
201706 -124.000 244.955 -167.159
201709 -100.000 246.819 -133.788
201712 -79.800 246.524 -106.890
201803 -67.600 249.554 -89.449
201806 -59.200 251.989 -77.577
201809 -107.600 252.439 -140.751
201812 -53.000 251.233 -69.662
201903 -17.800 254.202 -23.123
201906 -17.400 256.143 -22.432
201909 -15.600 256.759 -20.063
201912 -14.600 256.974 -18.761
202003 -18.000 258.115 -23.028
202006 -11.000 257.797 -14.090
202009 -16.000 260.280 -20.299
202012 -11.400 260.474 -14.452
202103 -8.600 264.877 -10.721
202106 -5.200 271.696 -6.320
202109 -5.800 274.310 -6.982
202112 -11.800 278.802 -13.976
202203 -9.400 287.504 -10.796
202206 -8.400 296.311 -9.361
202209 -9.800 296.808 -10.903
202212 -10.520 296.797 -11.704
202303 -13.250 301.836 -14.496
202306 -10.640 305.109 -11.515
202309 -6.360 307.789 -6.823
202312 -4.290 306.746 -4.618
202403 -4.880 312.332 -5.159
202406 -1.160 314.175 -1.219
202409 -0.700 315.301 -0.733
202412 -0.477 315.605 -0.499
202503 -0.400 319.799 -0.413
202506 -0.550 322.561 -0.563
202509 -0.110 324.800 -0.112
202603 -0.030 330.213 -0.030

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bio-Path Holdings Business Description

Address No. 2407, 625 Stanwix Street, Pittsburgh, PA, USA, 15222
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.